1-6 of 6
Howard Levy, PhD MBBChir
Close
Sort by
Journal Articles

The Crimson 1 Study: A Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptocog Alfa (activated) for on-Demand Treatment and Control of Bleeding Episodes in Subjects with Hemophilia A or Hemophilia B, with Inhibitors

Linda Neuman, MD, Shraddha Desai, PhD MS, Tom Knudsen, PhD DVM, Frank Del Greco, MBA, Howard Levy, PhD MBBChir
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-137806
Published: 2020
Journal Articles

Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog Alfa (activated) in the Treatment of Episodic Bleeding in Subjects with Inherited Bleeding Disorders

Linda Neuman, MD, Shraddha Desai, PhD MS, Frank Del Greco, MBA, Tom Knudsen, PhD DVM, Howard Levy, PhD MBBChir
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-137223
Published: 2020
Journal Articles

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Jill Reckless, Tom Knudsen, PhD DVM, Grant E. Blouse, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2420.
https://doi.org/10.1182/blood-2019-128971
Published: 2019
Journal Articles

The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable As Assessed By the Thrombin Generation Test in Hemophilia a Plasma

Tom Knudsen, PhD DVM, Brajesh Kumar, Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Grant E. Blouse, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1112.
https://doi.org/10.1182/blood-2019-130559
Published: 2019
Journal Articles

Opportunities for Improvement: The Lot of the Inhibitor Patient Is Not a Happy One

Frank V. McL. Booth, MA MSc BM BCh, Johnny Mahlangu, Howard Levy, PhD MBBChir
Journal: Blood
Blood (2018) 132 (Supplement 1): 5040.
https://doi.org/10.1182/blood-2018-99-111720
Published: 2018
Journal Articles

Phase 2/3 Trial of Subcutaneously Administered Marzeptacog Alfa (activated) an Engineered FVIIa in Hemophilia with Inhibitors - Pharmacokinetics, Pharmacodynamics, Safety and Efficacy

Howard Levy, PhD MBBChir, Levani Makhaldiani, Genadi Iosava, MD, Johnny Mahlangu, Marina V Kosinova, MD, Heghine Khacchatryan, MD, Frank Del Greco, MBA, Frank V. McL. Booth, MA MSc BM BCh
Journal: Blood
Blood (2018) 132 (Supplement 1): 1198.
https://doi.org/10.1182/blood-2018-99-112567
Published: 2018